The Effect of Linzagolix on Bone Mineral Density (BMD): Safety Results From a Dose-Ranging Trial [21J]

Abstract

INTRODUCTION:Linzagolix is a new, non-peptide, GnRH receptor antagonist being developed to treat endometriosis-associated pain (EAP). The EDELWEISS trial is a Phase 2b, double-blind, randomized, placebo-controlled, multicenter, dose-ranging trial in and Europe evaluating oral once daily doses of 50,